To date, HSCT is an ultimate therapy for XIAP deficiency, CDC42 C-terminal disease, or WDR1 deficiency refractory to conventional treatment (39, 53, 61). This evidence concerns the gene WDR1 and hyperinsulinemic hypoglycemia, familial, 4.